脑肿瘤患者的衰弱与术后结局:按肿瘤病因分组的系统综述
该系统综述遵循PRISMA指南,检索PubMed和Google Scholar,纳入52篇描述衰弱或KPS与原发性颅内肿瘤新关联的文献。研究按肿瘤类型分组:胶质母细胞瘤16篇、脑膜瘤13篇、前庭神经鞘瘤6篇、全部脑肿瘤17篇,其中7篇同时纳入衰弱指数和KPS。综述发现衰弱与多种术后结局(包括并发症和死亡率)相关,并指出既往综述多局限于特定衰弱指数且未按病因分层。
要点
- 系统综述纳入52篇文献,按肿瘤病因分组分析衰弱与术后结局的关系。
- 胶质母细胞瘤16篇、脑膜瘤13篇、前庭神经鞘瘤6篇、全部脑肿瘤17篇。
- 仅7篇研究同时纳入衰弱指数和KPS,衰弱与并发症和死亡率等术后结局相关。
核心结论
- 综述识别了脑肿瘤合并衰弱患者术后结局报告的若干模式。
- 既往脑肿瘤衰弱综述多局限于特定衰弱指数且不区分病变病因,可能忽略各肿瘤病理特有的关键细微差别。
研究设计与样本
- 遵循PRISMA指南的系统文献综述,检索PubMed和Google Scholar中关于衰弱、KPS和脑肿瘤结局的文章。
- 仅纳入描述衰弱或KPS与原发性颅内肿瘤新关联的文章,经排除标准后最终纳入52篇出版物。
- 纳入研究中胶质母细胞瘤16篇、脑膜瘤13篇、前庭神经鞘瘤6篇、全部脑肿瘤17篇,7篇同时纳入衰弱指数和KPS。
主要发现
- 恶性病变中16项研究聚焦胶质母细胞瘤,良性肿瘤中13项聚焦脑膜瘤、6项聚焦前庭神经鞘瘤。
- 17项研究将所有脑肿瘤患者合并分析。
- 7项研究同时将衰弱指数和KPS纳入分析。
- 研究将衰弱与多种术后结局相关联,包括并发症和死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Frailty has gained prominence in neurosurgical oncology, with more studies exploring its relationship to postoperative outcomes in brain tumor patients. As this body of literature continues to grow, concisely reviewing recent developments in the field is necessary. Here we provide a systematic review of frailty in brain tumor patients subdivided by tumor type, incorporating both modern frailty indices and traditional Karnofsky Performance Status (KPS) metrics. METHODS: Systematic literature review was performed using PRISMA guidelines. PubMed and Google Scholar were queried for articles related to frailty, KPS, and brain tumor outcomes. Only articles describing novel associations between frailty or KPS and primary intracranial tumors were included. RESULTS: After exclusion criteria, systematic review yielded 52 publications. Amongst malignant lesions, 16 studies focused on glioblastoma. Amongst benign tumors, 13 focused on meningiomas, and 6 focused on vestibular schwannomas. Seventeen studies grouped all brain tumor patients together. Seven studies incorporated both frailty indices and KPS into their analyses. Studies correlated frailty with various postoperative outcomes, including complications and mortality. CONCLUSION: Our review identified several patterns of overall postsurgical outcomes reporting for patients with brain tumors and frailty. To date, reviews of frailty in patients with brain tumors have been largely limited to certain frailty indices, analyzing all patients together regardless of lesion etiology. Although this technique is beneficial in providing a general overview of frailty's use for brain tumor patients, given each tumor pathology has its own unique etiology, this combined approach potentially neglects key nuances governing frailty's use and prognostic value.
引用
- Qureshi HM, Tabor JK, Pickens K, et al. Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology. J Neurooncol. 2023. PMID: 37624530. doi:10.1007/s11060-023-04416-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。